Insilico
Insilico gets IND approval for its AI-designed USP1 inhibitor
Insilico Medicine has made a significant breakthrough with its AI-designed USP1 inhibitor, ISM3091. The US Food and Drug Administration (FDA) has accepted Insilico’s Investigational New Drug (IND) application for this promising drug, marking a significant milestone for AI-assisted drug discovery. “The FDA’s acceptance of our IND for ISM3091 signifies that the FDA recognizes its potential …
Insilico Medicine, Arctoris announce technology partnership to discover new COVID-19 drugs
Reviewed by Emily Henderson, B.Sc.Jul 9 2020 Insilico Medicine, a biotechnology company developing an end-to-end drug discovery pipeline utilizing next-generation artificial intelligence, today announced a technology partnership with Arctoris, the world’s first fully automated drug discovery platform, offering remotely accessible, pre-optimized and fully validated R&D processes for its partners and clients globally. The partnership enables …
